-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting ATyr Pharma (NASDAQ:LIFE) & Gene Biotherapeutics (OTCMKTS:CRXM)
Contrasting ATyr Pharma (NASDAQ:LIFE) & Gene Biotherapeutics (OTCMKTS:CRXM)
aTyr Pharma (NASDAQ:LIFE – Get Rating) and Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and price targets for aTyr Pharma and Gene Biotherapeutics, as reported by MarketBeat.com.
Get aTyr Pharma alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
aTyr Pharma | 0 | 0 | 2 | 0 | 3.00 |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
aTyr Pharma currently has a consensus target price of $14.00, indicating a potential upside of 514.04%.
Profitability
This table compares aTyr Pharma and Gene Biotherapeutics' net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
aTyr Pharma | N/A | -50.01% | -44.98% |
Gene Biotherapeutics | N/A | N/A | N/A |
Earnings & Valuation
This table compares aTyr Pharma and Gene Biotherapeutics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
aTyr Pharma | $10.45 million | 6.25 | -$33.77 million | ($1.65) | -1.38 |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
Gene Biotherapeutics has lower revenue, but higher earnings than aTyr Pharma.
Institutional & Insider Ownership
65.6% of aTyr Pharma shares are held by institutional investors. 4.4% of aTyr Pharma shares are held by insiders. Comparatively, 49.8% of Gene Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
aTyr Pharma has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Gene Biotherapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
About aTyr Pharma
(Get Rating)
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
About Gene Biotherapeutics
(Get Rating)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
aTyr Pharma (NASDAQ:LIFE – Get Rating) and Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
納斯達克(ATyr Pharma:LIFE-GET Rating)和基因生物治療(Genetic BioTreateutics:CRTCMKTS:CRXM-GET Rating)都是小盤醫藥公司,但哪隻股票更優越?我們將根據這兩家公司的風險、估值、機構所有權、收益、盈利能力、股息和分析師的建議來比較它們的實力。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for aTyr Pharma and Gene Biotherapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道,這是aTyr Pharma和gene BioTreateutics最近的評級和目標價細分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
aTyr Pharma | 0 | 0 | 2 | 0 | 3.00 |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
阿泰爾製藥公司 | 0 | 0 | 2 | 0 | 3.00 |
基因生物治療學 | 0 | 0 | 0 | 0 | 不適用 |
aTyr Pharma currently has a consensus target price of $14.00, indicating a potential upside of 514.04%.
ATyr Pharma目前的共識目標價為14.00美元,表明潛在上行空間為514.04%。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
aTyr Pharma | N/A | -50.01% | -44.98% |
Gene Biotherapeutics | N/A | N/A | N/A |
淨利潤率 | 股本回報率 | 資產回報率 | |
阿泰爾製藥公司 | 不適用 | -50.01% | -44.98% |
基因生物治療學 | 不適用 | 不適用 | 不適用 |
Earnings & Valuation
收益與估值
This table compares aTyr Pharma and Gene Biotherapeutics' revenue, earnings per share and valuation.
下表比較了泰爾製藥公司和基因生物治療公司的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
aTyr Pharma | $10.45 million | 6.25 | -$33.77 million | ($1.65) | -1.38 |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
阿泰爾製藥公司 | 1045萬美元 | 6.25 | -3,377萬元 | ($1.65) | -1.38 |
基因生物治療學 | 不適用 | 不適用 | -$520,000.00 | 不適用 | 不適用 |
Gene Biotherapeutics has lower revenue, but higher earnings than aTyr Pharma.
基因生物療法的收入低於aTyr Pharma,但收益高於aTyr Pharma。
Institutional & Insider Ownership
機構與內部人持股
65.6% of aTyr Pharma shares are held by institutional investors. 4.4% of aTyr Pharma shares are held by insiders. Comparatively, 49.8% of Gene Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
65.6%的aTyr Pharma股票由機構投資者持有。ATyr Pharma 4.4%的股份由內部人士持有。相比之下,基因生物治療公司49.8%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司的長期表現將好於大盤。
Volatility and Risk
波動性和風險
aTyr Pharma has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Gene Biotherapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
ATyr Pharma的貝塔係數為1.31,這表明其股價的波動性比標準普爾500指數高出31%。相比之下,基因生物治療公司的貝塔係數為0.73,這表明其股價的波動性比標準普爾500指數低27%。
About aTyr Pharma
關於阿泰爾製藥公司
(Get Rating)
(獲取評級)
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
ATyr Pharma,Inc.是一家生物治療公司,在美國從事基於新免疫途徑的藥物的發現和開發。該公司的主要候選藥物是efzofitimod,這是一種NRP2的選擇性調節劑,正在進行肺結節病的第二階段臨牀試驗;以及1b/2a階段的臨牀試驗,用於治療其他間質性肺部疾病,如慢性過敏性肺炎和與ILD相關的結締組織疾病。該公司還在開發ATYR2810,這是一種完全人源化的單抗,正處於臨牀前開發階段,用於治療實體腫瘤。它與Kyorin製藥株式會社就用於ILDS的efzofitimod的開發和商業化達成了合作和許可協議。該公司成立於2005年,總部設在加利福尼亞州聖地亞哥。
About Gene Biotherapeutics
關於基因生物治療學
(Get Rating)
(獲取評級)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
基因生物療法公司是一家臨牀階段生物技術公司,在美國專注於血管生成基因療法生物療法的開發和商業化,用於治療心血管疾病。該公司的主導候選產品是Generx,這是第三階段臨牀試驗中的一種血管生成基因治療候選產品,用於潛在地治療晚期冠狀動脈疾病引起的心肌缺血和頑固性心絞痛患者。它還在開發與缺血相關的心血管和腦治療適應症的Generx。基因生物治療公司與Fujifilm DiSynth生物技術公司達成協議,將生產用於第三階段臨牀評估的Generx血管生成基因治療產品。該公司前身為紅豆杉Cardium製藥集團,並於2018年1月更名為基因生物治療公司。基因生物治療公司成立於2003年,總部設在加利福尼亞州聖地亞哥。
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受aTyr Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對aTyr Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧